Results 151 to 160 of about 6,340 (200)

Role of Obeticholic Acid, a Farnesoid X Receptor Agonist, in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. [PDF]

touchREV Endocrinol
Kamrul-Hasan A, Mondal S, Nagendra L, Sasikanth T, Ahammed A, Rahman S, Wickramarachchi A, Parajuli N, Khatiwada S, Dutta D.   +9 more
europepmc   +1 more source

Obeticholic acid ameliorates sepsis-induced renal mitochondrial damage by inhibiting the NF-κb signaling pathway. [PDF]

Ren Fail
Jing D, Liu J, Qin D, Lin J, Li T, Li Y, Duan M.   +6 more
europepmc   +1 more source

The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Medicine (Baltimore)
Zhao J, Li B, Zhang K, Zhu Z.
europepmc   +1 more source

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. [PDF]

PLoS One
Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.   +4 more
europepmc   +1 more source

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al. [PDF]

Digestive Diseases and Sciences, 2018
openaire   +2 more sources

Cirrhosis : reviewing the literature and future perspectives [PDF]

, 2016
Geerts, Anja, Van Vlierberghe, Hans, Verhelst, Xavier   +2 more
core  

Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid. [PDF]

J Pharmacol Exp Ther
Meshanni JA, Lee JM, Vayas KN, Sun R, Jiang C, Guo GL, Gow AJ, Laskin JD, Laskin DL.   +8 more
europepmc   +1 more source

Edaravone and obeticholic acid protect against cisplatin-induced heart toxicity by suppressing oxidative stress and inflammation and modulating Nrf2, TLR4/p38MAPK, and JAK1/STAT3/NF-κB signals. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
El-Shoura EAM, Hassanein EHM, Taha HH, Shalkami AS, Hassanein MMH, Ali FEM, Bakr AG.   +6 more
europepmc   +1 more source

Dual Amylin and Calcitonin Receptor Agonists: A Novel Treatment for Obesity and Related Co-Morbidities [PDF]

, 2017
Gydesen, Sofie
core  

From the Editor’s desk...: May 2016 [PDF]

, 2016
Bataller, R, Berg, T, Jalan, R, Moreau, R, Zucman-Rossi, J   +4 more
core